摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[1-(3,5-dichlorophenyl)ethyl]methylamine | 1225838-76-5

中文名称
——
中文别名
——
英文名称
[1-(3,5-dichlorophenyl)ethyl]methylamine
英文别名
2-(3,5-Dichlorophenyl)propan-1-amine
[1-(3,5-dichlorophenyl)ethyl]methylamine化学式
CAS
1225838-76-5
化学式
C9H11Cl2N
mdl
——
分子量
204.099
InChiKey
GKRJXFPWEOSJAK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    26
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    [1-(3,5-dichlorophenyl)ethyl]methylamine4-[2-carboxy-1-(4-fluoro-phenyl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下, 以 DMF (N,N-dimethyl-formamide) 为溶剂, 反应 0.5h, 生成 [4-[2-[1-(3,5-dichloro-phenyl)-ethyl]methyl-carbamoyl]-1-(4-fluoro-phenyl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 、 [4-[2-[1-(3,5-dichloro-phenyl)-ethyl]methyl-carbamoyl]-1-(4-fluoro-phenyl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester
    参考文献:
    名称:
    [EN] N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ AND/ OR SEROTONIN REUPTAKE INHIBITORS
    [FR] COMPOSES DE N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE EN TANT QU'INHIBITEURS DE RECAPTAGE DE LA TACHYKININE ET/OU DE LA SEROTONINE
    摘要:
    本发明涉及式(1)的杂环衍生物,其中R1代表一个5或6成员杂芳基团,在其中5成员杂芳基团至少含有氧、硫或氮中选择的一个杂原子,而6成员杂芳基团含有1至3个氮原子,或者R1代表一个4、5或6成员杂环基团,其中所述的5或6成员杂芳基或4、5或6成员杂环基团可以选择地被1至3个取代基取代,所述取代基可以相同或不同,选择自(CH2)pR6,其中p为零或1至4的整数,其中R和R2-R6如描述中定义,并且其药学上可接受的盐和溶剂化合物;其制备方法及其在通过催产素介导的疾病和/或通过选择性抑制血清素再摄取转运蛋白的治疗中的用途。
    公开号:
    WO2004005255A1
  • 作为产物:
    描述:
    3’,5’-二氯苯乙酮甲胺 在 sodium tetrahydroborate 作用下, 以 甲醇 为溶剂, 反应 20.0h, 生成 [1-(3,5-dichlorophenyl)ethyl]methylamine
    参考文献:
    名称:
    [EN] N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ AND/ OR SEROTONIN REUPTAKE INHIBITORS
    [FR] COMPOSES DE N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE EN TANT QU'INHIBITEURS DE RECAPTAGE DE LA TACHYKININE ET/OU DE LA SEROTONINE
    摘要:
    本发明涉及式(1)的杂环衍生物,其中R1代表一个5或6成员杂芳基团,在其中5成员杂芳基团至少含有氧、硫或氮中选择的一个杂原子,而6成员杂芳基团含有1至3个氮原子,或者R1代表一个4、5或6成员杂环基团,其中所述的5或6成员杂芳基或4、5或6成员杂环基团可以选择地被1至3个取代基取代,所述取代基可以相同或不同,选择自(CH2)pR6,其中p为零或1至4的整数,其中R和R2-R6如描述中定义,并且其药学上可接受的盐和溶剂化合物;其制备方法及其在通过催产素介导的疾病和/或通过选择性抑制血清素再摄取转运蛋白的治疗中的用途。
    公开号:
    WO2004005255A1
点击查看最新优质反应信息

文献信息

  • N-substituted-aminomethyl cyclopropyl ketone derivatives or salts thereof and production process therefor
    申请人:——
    公开号:US20020156323A1
    公开(公告)日:2002-10-24
    Novel N-substituted-aminomethyl cyclopropyl ketone derivatives are represented by following Formula (1): 1 wherein R 1 , R 2 and R 3 are each a hydrogen atom or an aliphatic hydrocarbon group; and R 4 and R 5 are each a hydrogen atom or an arylmethyl group which may have a substituent, where at least one hydrogen atom or aryl group as a substituent is combined with a carbon atom in the methyl moiety of the arylmethyl group, and at least one of R 4 and R 5 is an arylmethyl group which may have a substituent. These compounds are useful for the preparation of aminomethyl cyclopropyl ketone derivatives and 2-amino-1-cyclopropylethanol derivatives or salts thereof.
    新型N-取代氨甲基环丙基酮衍生物由以下式(1)表示:其中R1、R2和R3分别是氢原子或脂肪烃基;R4和R5分别是氢原子或苄基基团,可能具有取代基,其中至少有一个氢原子或苄基作为取代基与苄基基团的甲基部分中的碳原子结合,且R4和R5中至少一个是可能具有取代基的苄基基团。这些化合物适用于制备氨甲基环丙基酮衍生物和2-氨基-1-环丙基乙醇衍生物或其盐。
  • [EN] CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES D'AMINE CYCLIQUES, PROCEDES DE PREPARATION DE CEUX-CI ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:GLAXO GROUP LTD
    公开号:WO2004099143A1
    公开(公告)日:2004-11-18
    A compound of formula (I) wherein R represents a radical selected from i) ii) iii) iv) where the substituents R1, R2, R3, R4, R4, R7 and the indices m, n and p are as defined in the description; or pharmaceutically acceptable salts and solvates thereof; processes for their preparation to pharmaceutical compositions containing them and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.
    式(I)的化合物,其中R代表从i)ii)iii)iv)中选择的基团,其中取代基R1、R2、R3、R4、R5、R6、R7和指数m、n和p如描述中所定义;或其药学上可接受的盐和溶剂;它们的制备方法到含有它们的药物组合物以及它们在治疗由速效肽激酶介导的病症和/或通过选择性抑制血清素再摄取转运蛋白介导的病症中的应用。
  • Chemical compounds
    申请人:Alvaro Giuseppe
    公开号:US20060128752A1
    公开(公告)日:2006-06-15
    The present invention relates to cyclic amine derivatives of formula(l) wherein R represents halogen, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; R 1 represents hydrogen, halogen, C 3-7 cycloalkyl, hydroxy, nitro, cyano or C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 represents hydrogen or C 1-4 alkyl; R 3 and R 4 independently represent hydrogen, cyano, C 1-4 alkyl or R 3 together with R 4 represents C 3-7 cycloalkyl; R 5 represents trifluoromethyl, S(O) t C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, halogen or cyano; R 6 represents hydrogen or (CH 2 )rR 7 ; R 7 represents hydrogen, C 3 7 cycloalkyl, NH(C 1-4 alkylOC 1-4 alkoxy), NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , OC(O)NR 9 R 8 , NR 8 C(O)R 9 or C(O)NR 9 R 8 ; R 9 and R 8 independently represent hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m represents zero or an integer from 1 to 4; n represents 1 or 2; p is zero or an integer from 1 to 3; q is an integer from 1 to 3; r is an integer from 1 to 4; t is 0, 1 or 2; provided that when m is 0, p is 2, q , r and n represent 1, R 1 , R 2 ,R 3 , R 4 , R 5 and R 7 are hydrogen and R is chlorine, R 5 is not iodine; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of serotonin reuptake transporter protein.
    本发明涉及式(I)的环状胺衍生物,其中R代表卤素、C1-4烷基、氰基、C1-4烷氧基、三氟甲基或三氟甲氧基;R1代表氢、卤素、C3-7环烷基、羟基、硝基、氰基或C1-4烷基,可选地被卤素、氰基或C1-4烷氧基取代;R2代表氢或C1-4烷基;R3和R4独立地代表氢、氰基、C1-4烷基或R3和R4一起代表C3-7环烷基;R5代表三氟甲基、S(O)tC1-4烷基、C1-4烷基、C1-4烷氧基、三氟甲氧基、卤素或氰基;R6代表氢或(CH2)rR7;R7代表氢、C37环烷基、NH(C1-4烷基OC1-4烷氧基)、NH(C1-4烷基)、N(C1-4烷基)2、OC(O)NR9R8、NR8C(O)R9或C(O)NR9R8;R9和R8独立地代表氢、C1-4烷基或C3-7环烷基;m代表零或1至4的整数;n代表1或2;p为零或1至3的整数;q为1至3的整数;r为1至4的整数;t为0、1或2;但当m为0,p为2,q、r和n均为1,R1、R2、R3、R4、R5和R7均为氢,R为氯时,R5不为碘;以及其药学上可接受的盐和溶剂化合物;其制备方法和在治疗由粘附素介导和/或选择性抑制血清素再摄取转运蛋白介导的疾病中的应用。
  • N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors
    申请人:Alvaro Giuseppe
    公开号:US20060058348A1
    公开(公告)日:2006-03-16
    The present invention relates to heterocyclic derivatives of formula (I) wherein R represents halogen, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; R 1 represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R 1 represents a 4, 5 or 6 membered heterocyclic group, wherein saids 5 or 6 membered heteroaryl or the 4, 5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH 2 ) p R 6 , wherein p is zero or an integer from 1 to 4 and R 6 is selected from: halogen, C 1-4 alkoxy, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy, hydroxy, cyano, nitro, trifluoromethyl, carboxy, NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 NH(C 3-7 cycloalkyl), N(C 1-4 alkyl)(C 3-7 cycloalkyl); NH(C 1-4 alkylOC 1-4 alkoxy), OC(O)NR 7 R 8 , NR 8 C(O)R 7 or C(O)NR 7 R 8 ; R 2 represents hydrogen, or C 1-4 alkyl; R 3 and R 4 independently represent hydrogen, C 1-4 alkyl or R 3 together with R 4 represents C 3-7 cycloalkyl; R 5 represents trifluoromethyl, S(O) q C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, halogen or cyano; R 7 and R 8 independently represent hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; L is a single or a double bond; n is an integer from 1 to 3; m is zero or an integer from 1 to 3; q is zero or an integer from 1 to 2; provided that a) when L is a double bond, R 1 is not an optionally substituted 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms; b) the group R 1 is linked to the carbon atom shown as * via a carbon atom; and c) when the heteroatom contained in the group R 1 is substituted, p is not zero; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.
    本发明涉及公式(I)的杂环衍生物,其中R代表卤素、C1-4烷基、氰基、C1-4烷氧基、三氟甲基或三氟甲氧基;R1代表一个5或6成员的杂芳基团,其中5成员杂芳基团含有至少一个从氧、硫或氮中选择的杂原子,6成员杂芳基团含有从1到3个氮原子,或R1代表一个4、5或6成员的杂环基团,其中所述的5或6成员杂芳基或4、5或6成员的杂环基团可以选修为1至3个取代基,所述取代基可以是相同的或不同的,选自(CH2)pR6,其中p为零或1至4的整数,R6选自:卤素、C1-4烷氧基、C1-4烷基、C3-7环烷基、C1-4烷基(可选地取代为卤素、氰基或C1-4烷氧基)、羟基、氰基、硝基、三氟甲基、羧基、NH(C1-4烷基)、N(C1-4烷基)2NH(C3-7环烷基)、N(C1-4烷基)(C3-7环烷基);NH(C1-4烷基OC1-4烷氧基)、OC(O)NR7R8、NR8C(O)R7或C(O)NR7R8;R2代表氢或C1-4烷基;R3和R4独立地代表氢、C1-4烷基或R3与R4一起代表C3-7环烷基;R5代表三氟甲基、S(O)qC1-4烷基、C1-4烷基、C1-4烷氧基、三氟甲氧基、卤素或氰基;R7和R8独立地代表氢、C1-4烷基或C3-7环烷基;L是单键或双键;n是1至3的整数;m是零或1至3的整数;q是零或1至2的整数;前提是a)当L是双键时,R1不是可选修饰的含有至少一个从氧、硫或氮中选择的杂原子的5或6成员杂芳基团,6成员杂芳基团含有从1到3个氮原子;b)R1团与所示碳原子通过碳原子相连;c)当R1团中含有的杂原子被取代时,p不为零;以及其药学上可接受的盐和溶剂酸化物;它们的制备过程及其在治疗由Tachykinins介导和/或通过选择性抑制血清素再摄取转运蛋白介导的疾病中的用途。
  • Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them
    申请人:Alvaro Giuseppe
    公开号:US20070073061A1
    公开(公告)日:2007-03-29
    A compound of formula (I) wherein R is a radical selected from in which R 7 is halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; p is an integer from 0 to 3; R 1 is hydrogen, halogen, cyano, C 2-4 alkenyl, C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 is hydrogen or C 1-4 alkyl; R 3 and R 4 independently are hydrogen, C 1-4 alkyl or R 3 together with R 4 is C 3-7 cycloalkyl; R 5 is phenyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl, naphthyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl, a 9 to 10 membered fused bicyclic heterocyclic group substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl or R 5 is a 5 or 6 membered heteroaryl group substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl; R 6 is hydrogen or (CH 2 )qR 8 ; R 8 is hydrogen, C 3-7 cycloalkyl, C 1-4 alkoxy, amine, C 1-4 alkylamine, (C 1-4 alkyl) 2 amine, OC(O)NR 9 R 10 or C(O)NR 9 R 10 ; R 9 and R 10 independently are hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m is zero or 1; n is 1 or 2; q is an integer from 1 to 4; r is 1 or 2; or pharmaceutically acceptable salts and solvates thereof; processes for their preparation to pharmaceutical compositions containing them and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.
    化合物的结构式为(I),其中R是选择自以下基团的基团,其中R7是卤素、氰基、C1-4烷基、C1-4烷氧基、三氟甲基或三氟甲氧基;p是从0到3的整数;R1是氢、卤素、氰基、C2-4烯基、C1-4烷基(可选择性地被卤素、氰基或C1-4烷氧基取代);R2是氢或C1-4烷基;R3和R4分别是氢、C1-4烷基或R3与R4结合形成C3-7环烷基;R5是苯基,其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或(SO)rC1-4烷基;萘基,其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或(SO)rC1-4烷基;或9到10个成员的融合双环杂环基团,其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或(SO)rC1-4烷基;R5也可以是5或6个成员的杂芳基团,其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或(SO)rC1-4烷基;R6是氢或(CH2)qR8;R8是氢、C3-7环烷基、C1-4烷氧基、胺、C1-4烷基胺、(C1-4烷基)2胺、OC(O)NR9R10或C(O)NR9R10;R9和R10分别是氢、C1-4烷基或C3-7环烷基;m为零或1;n为1或2;q是从1到4的整数;r为1或2;或其药学上可接受的盐和溶剂;制备它们的方法,含有它们的药物组合物以及它们在治疗由Tachykinins和/或通过选择性抑制血清素再摄取转运蛋白介导的疾病中的用途。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐